NPPB and heart failure: Finally, and despite prolonged treatment with excellent previous tolerability and clinical benefit, sorafenib-induced cardiac toxicity (both AF and heart failure) could not be ruled out based on previously described clinical findings, NT-proBNP, and LVEF evolution profile.